Drug Topics April 4, 2024
Lauren Biscaldi, MS, Managing Editor

The FDA has approved iloperidone tablets (Fanapt) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. The atypical antipsychotic agent was initially approved in 2009 for the acute treatment of schizophrenia.1

Bipolar disorder affects approximately 2.8% of adults in the United States; 83% of these cases are considered severe. Bipolar I disorder with manic or mixed episodes comprise a subset of the approximately 10 million Americans living with the disease.

“Many patients are still unable to find suitable treatment options for effectively managing bipolar disorder,” said Stephen Stahl, MD, PhD, professor of psychiatry at the University of California San Diego, in a press release.1 “Tailoring the right treatment for the right patient is...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
FDA targets health inequality by improving at-home devices
STAT+: FDA is criticized for taking a ‘ministerial’ role in sorting out some pharma patents
We now know Tome’s gene editing target
STAT+: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more
FDA Updates for the Week of May 6: An Approval, a Delay and Two Ad Comm Meetings

Share This Article